Did I get this one wrong? Or is my investment thesis still intact and it’s just a question of being patient with this one?

What’s going wrong?

Demand for scientific instruments was weak last year, especially in the US. But I expected this to eventually show signs of recovery.

Congressional appropriators blocked the Trump administration’s proposed funding cuts. In its March update, however, Judges Scientific was cautious around this:

The uncertainty emanating from the USA is disruptive to our business and the reduction in federal funding of scientific research remains a source of great unpredictability in spite of recent congressional moves to restore it.

That’s not a great sign. But there’s also something else to pay attention to. The 2026 outlook for the firm’s Geotek subsidiary is also uninspiring. 

Geotek conducts coring expeditions with earth scientists. These are extremely profitable, but they’re also very infrequent. 

Judges Scientific isn’t expecting another expedition in 2026. But does that mean my thesis for the stock is busted?

Thesis busted?

I’m well down on my investment in Judges Scientific. But I actually think there were some real positives in the firm’s update.

One is that it looks like it’s a question of when – not if – research funding will flow again. And I’m not in a rush with this one.

Another is that there was some good news about Geotek. Since 2022, the business has managed two expeditions. The next expedition is expected to come in early 2027. And the frequency after that is anticipated to be roughly three every four years.

That won’t make a difference in 2026. But it could be a huge boost to revenues and profits over the long term.

Given this, I’m still pretty optimistic about the stock. There is, however, something that I’m more aware of now than I was before.

Cyclicality

Most businesses go through ups and downs. But it’s worth noting that Judges Scientific is more prone to this than others.

That’s not an accident. It comes from the fact that the company’s equipment is extremely expensive and highly technical.

This isn’t necessarily a bad thing. It creates high barriers to entry and makes the firm difficult to compete with.

It does, however, increase cyclicality. Uncertain environments have a bigger effect on new purchases than replacement parts.

That’s why it’s so important to think long-term with this type of business. But from that perspective, I think things still look good.

What I’m doing

Judges Scientific shares are much cheaper than they were when I started buying them. But I don’t think the business is fundamentally worse.

Given this, why would I think about selling? If anything, the equation looks more favourable to me from a buying perspective.

For what it’s worth, the analysts are also on my side with this one. The average price target is 52.48% above the stock’s current level.

Source: TradingView

That’s about in line with my own estimate of what the stock is worth and it implies a 34% discount to fair value. 

Given this, I’m looking to add to my investment. I’m mindful of concentration risk, but I can add a bit while staying diversified overall.

Should you invest £5,000 in Judges Scientific Plc right now?

When investing expert Mark Rogers and his team have a stock tip, it can pay to listen. After all, the flagship Twelfth Magpie Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Judges Scientific Plc made the list?

Stephen Wright owns shares in Judges Scientific.

The post Down 26% this year! Should I keep buying shares in this UK growth company? appeared first on The Twelfth Magpie.

So how big does an ISA need to be to generate the same amount of money as the State Pension?

Let’s find out.

Running the numbers

Following the 4% withdrawal rule, an ISA would need to reach around £313,690 to generate that £12,547.60 a year.

Obviously, that’s a pretty chunky sum. Yet while it may feel out of reach, even a 40-year-old starting from scratch with just £500 to spare each month can hit this milestone before turning 60.

Here’s how. That £500 a month invested at a compounded annual return of 10% for 19 years will grow to £338,007.80. That means at the age of 59, this portfolio would generate around £1,000 more in passive income, landing at £13,520.31.

So which UK stocks should investors be looking at today to aim for that 10% annualised return?

Could this overlooked compounder do the job?

The UK stock market’s home to a growing list of proven compounders that have quietly outpaced the market for decades. And in 2026, one stock that’s started getting more institutional attention is Judges Scientific (LSE:JDG).

As a quick introduction, the company’s a scientific instruments group that acquires small, niche businesses making highly specialised laboratory and measurement equipment. Its customers include universities, research institutions, and industrial manufacturers worldwide.

So can it generate a 10% long term annualised return?

There are never any guarantees when it comes to investing. However, Judges Scientific’s bolt-on, acquisition-led growth model is a proven one used by many successful compounders.

By acquiring small founder-owned businesses at sensible prices, keeping existing management in place, and letting the earnings compound quietly over time, the results can be tremendous. And shareholders have already seen a glimpse of the returns this can generate.

Fun fact: over the last decade, Judges Scientific shares have averaged a 12.3% annualised return. The question now is, can it continue?

What could go wrong?

Despite its impressive track record, the company has had its fair share of challenges lately.

The freezing of US federal research grants due to budgetary concerns has taken a toll on organic growth. And with inflationary pressures on specialised components and skilled engineering talent driving up costs, margins have also gotten squeezed.

While frustrating, this does appear to be a temporary problem. But it nonetheless reveals a previously unexpected cyclical element and political sensitivity of Judges Scientific’s cash flows.

Fortunately, some early signs of improvement are emerging in 2026. However, even if the company gets back on track as expected, it nonetheless still needs to find new quality bolt-on acquisition targets to maintain long-term growth. And overpaying for acquisitions that underperform could meaningfully dent long-term returns.

Nevertheless, in my opinion, Judges Scientific offers a genuinely compelling case. It has a proven business model, a fragmented market full of acquisition targets, and a management team seemingly successfully steering the company through a difficult period.

So for a 40-year-old building an ISA to replace or piggyback the State Pension, this looks like the kind of quiet compounder that’s worth considering.

Should you invest £5,000 in Judges Scientific Plc right now?

When investing expert Mark Rogers and his team have a stock tip, it can pay to listen. After all, the flagship Twelfth Magpie Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Judges Scientific Plc made the list?

Zaven Boyrazian does not hold any positions in the companies mentioned.

The post How big does an ISA need to be to replace the State Pension? appeared first on The Twelfth Magpie.

There are no shortcuts. But with time on your side, you might not need as much cash as you think to join the ranks of the ISA millionaires.

No savings at 40?

In a lot of ways, millennials have had things pretty good compared to our parents or grandparents. And I say this as one of them myself.

More of my cohort went to university than earlier generations. Travel is also much more accessible and things like Netflix exist.

Financially, though, things are tough. House prices have grown faster than wages, interest rates are low, and employment is less predictable.

Given all this, it’s easy to see how millennials might put off saving. But even getting started at 40, it’s not too late.

How much do you need?

The long-term average return from the FTSE 100 has been around 6.5% a year. And a 40-year-old in the UK qualifies for the State Pension in 28 years.

Working backwards, that’s enough to turn £171,300 into £1m by retirement. But that’s no good to someone starting from scratch.

The good news is that investing a fixed amount each month could achieve the same result. And the amount required is £1,053. For a lot of people, that might be a lot more realistic than £171,300 at the outset. The next question is what to invest in.

Growth stocks

Reinvesting dividends can be a viable way of building wealth. But I don’t think it’s always the most efficient – even in a Stocks and Shares ISA.

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.

There’s no dividend tax to worry about. ISA advantages, however, don’t get you away from stamp duty and transaction costs.

Even with brokers that don’t charge commissions, those can still add up. That’s why I prefer growth stocks for building wealth. 

Reinvesting profits at high rates of return can be a powerful force. And I think the UK has some interesting companies that can do this.

Small-cap growth

Shares of Judges Scientific (LSE:JDG) have fallen 58.33% from their highs. But I think this could be a really compelling time to take a look.

The big challenge recently has been weak research funding in the US. But it looks like things are starting to pick up on that front.

Judges hasn’t reported signs of a recovery yet, but I think it might only be a matter of months. On top of this, the long-term picture is encouraging. 

The firm boosts its organic growth by acquiring other businesses. And its size means it should have a lot of opportunities for growth still ahead.

The road to £1m

Buying businesses can be risky – a bit like investing in the stock market. That’s something to keep in mind with Judges Scientific. 

The best way for investors to do this is by building a diversified portfolio. And investing on a regular basis can be a great way of doing this.

Aiming to become an ISA millionaire takes time. But that means the sooner you get started, the better your chances.

Stephen Wright owns shares in Judges Scientific and Netflix.

The post No savings at 40? Here’s how much you need to invest to aim for a million in a Stocks and Shares ISA appeared first on The Twelfth Magpie.

Lots do not – and last tax year’s ISA contribution deadline this month passed for ever.

But the good news is that, as one door closes, another opens.

This month saw the start of a new tax year – and with it a whole new ISA contribution allowance for most UK investors.

Here is how not using that could mean missing out on a powerful opportunity to build a second income from dividend shares.

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.

Money for nothing

Many shares pay dividends – basically a way for the company to use spare cash to reward shareholders.

Not all do, though, which is why savvy investors choose carefully and spread their portfolios over a diversified range of companies.

Say someone put £20k into such a diversified portfolio today and was able to compound it at 6% annually for 25 years, before then earning a 6% dividend yield on it. Doing that would generate an annual second income at that point of £5,150.

Now, someone could do that without using an ISA – for example, simply using a share-dealing account. Indeed, that approach would not be constrained by the contribution allowances imposed on ISAs.

Still, I think not using a Stocks and Shares ISA could be throwing away an opportunity for a couple of reasons.

First, the ability of dividends to compound tax-free inside the ISA wrapper should mean it is easier to hit a specific annual compounding target, like the 6% I mentioned, than if some dividends each year had to fund tax payment.

Secondly, the discipline of a fixed annual deadline can help the procrastinators move from dreaming mode to action mode. Without that, their goals of a second income may never amount to anything more than dreams.

Being realistic about goals can still be lucrative

Is a 6% compound annual gain or yield realistic?

The compound annual gain includes share price rises, though any price falls would eat into it.

One share I think investors ought to consider right now both for its price and dividend prospects is lab instrument maker Judges Scientific (LSE: JDG).

At first glance this may seem like an odd choice. The dividend yield is 2.5%, which is fine but not special by market standards, while the price of 57 times earnings looks expensive at first. After all, the company continues to face risks like a funding freeze hurting orders from US research institutions.

But last year’s almost basic earnings per share almost halved.

I hope they can recover and the company can return to historic growth norms thanks to its specialist product portfolio and ongoing expansion strategy. Then, today’s price — 22% lower than a year ago — could turn out to be a long-term bargain.

Even last year’s sharply reduced basic earnings per share still (just) covered the dividend. A 10% dividend per share increase continued Judges’ history of double-digit percentage increases.

Its well-honed business model could help keep such rises coming.

The post Missed the ISA deadline? Ignoring the next one could mean throwing away a £5,150 annual second income opportunity! appeared first on The Twelfth Magpie.

There are however, big discounts still on offer. So I don’t think investors should be put off by a rising stock market.

Vistry

I was thinking of buying shares in FTSE 250 housebuilder Vistry (LSE:VTY). But the stock surged 15% on Wednesday (8 April) which is annoying. 

A rising price though, doesn’t automatically mean a stock’s expensive. And I think this is a good illustration of that point. 

The main challenge facing the firm though, is still there. It’s the fact that affordability issues mean its existing inventory isn’t shifting. Like most other builders, the company’s selling these at lower prices. But that isn’t a good thing for margins in the short term.

Fortunately, Vistry’s in a unique position. It operates through partnerships with housing associations, local authorities, and rental agencies. I think these connections are set to be a huge advantage. The UK has just launched a £39bn plan for affordable housing that lasts 10 years.

Vistry’s existing relationships mean a lot of this could come the company’s way. And the current market value is £1.1bn. In my view, that’s still a very attractive equation. So despite the rising share price, I’m still interested in buying. 

Judges Scientific

Unlike a lot of UK shares, Judges Scientific (LSE:JDG) didn’t really move on Wednesday. As a result, the stock still looks cheap to me. 

The scientific instrument firm’s earnings per share are set to fall in 2026, which isn’t a good sign. But it’s worth looking more closely at why. 

One reason is to do with Geotek – its coring subsidiary. Contracts in this business are infrequent and there isn’t one expected in 2026.  Management however, expects roughly three every four years going forward. So that means this year’s earnings will be unusually low. 

Another reason is the situation in the US. The administration’s attempts to research funding had been weighing on demand for scientific instruments. This however, has been shot down by Congress. In fact, it’s been replaced with increases to the National Institutes for Health’s budget. 

Judges Scientific isn’t seeing increased demand yet, but I think it’s coming. And if I’m right, the stock’s a lot cheaper than it looks. I expect 2026 to be a bad year on paper for the business. But I’m expecting a strong rebound thereafter, which is why I think the stock looks cheap.

Time to buy?

The stock market has just had a big boost from easing geopolitical tensions. So investors might think it’s not the time to be buying. My view though, is that this is a mistake. There are still UK stock that look attractive to me, even with prices generally heading higher. 

At times like this, there are two things to remember: higher prices don’t automatically mean stocks are overvalued; and not every stock is the same. A rising market doesn’t mean that everything’s more expensive.

Investors who keep these two points in mind are in a good position to look for potential opportunities. And that’s what I’m doing right now.

The post With share prices rising, is now the time to hold off buying stocks? appeared first on The Twelfth Magpie.

In some cases, shares that fell sharply in March are worth a look in April. But some of the most interesting are where investors aren’t paying attention.

Volatility

In times of volatility, investors often look for safety. And that usually means focusing on whatever their highest-conviction ideas are. That’s a natural thing to do. But it can often result in significant discounts in shares that don’t get the attention they deserve. 

When this happens, under-the-radar companies can offer investors unusually good value. These are stocks outside the FTSE 100 or the S&P 500. In the short term, this can result in share prices that fall sharply. But for investors with a long-term perspective, it can create huge opportunities.

That’s what I’m seeing right now. While analysts are focusing on Rolls-Royce and Meta Platforms, other names have started to look attractive.

Judges Scientific

Judges Scientific (LSE:JDG) is a UK growth stock with a £275m market value. The share price is down 12% in the last month. 

I think this is a terrific company facing short-term challenges. Its growth strategy involves acquiring and improving smaller businesses. This can be risky, but Judges Scientific has some unique long-term advantages. It’s highly specialised and focuses on relatively small targets. 

Both of these naturally restrict competition. And this has allowed the firm to do deals at extremely attractive multiples. On top of this, the company has an excellent reputation. A decentralised structure makes them an attractive buyer for anyone looking to sell.

The firm’s sales are still falling. But with Congress striking down cuts to US research funding, I think a recovery might be closer than investors realise.

QXO

QXO (NYSE:QXO) is a US supplier of building materials. But it’s got a lot more going on in terms of growth prospects than this suggests.

The company is targeting $50bn in revenues by 2035. That’s absolutely huge for a company with a current market value of $13bn. 

The plan is to get there through a series of acquisitions. And CEO Brad Jacobs has a record of doing this that isn’t just good – it’s great. QXO announced the acquisition of Kodiak Building Partners in March.

This adds around $2bn in revenues, but it also highlights the big risk. The firm issued around 13m shares in the process. And the potential for ongoing dilution is something investors will need to keep an eye on.

As I see it though, the long-term growth strategy remains firmly intact. So I see the stock falling 21% as a chance to add to my investment.

Growth stocks

It’s no coincidence that the opportunities I’m seeing right now are mostly in growth stocks. In times of stress, investors look for relative certainty. This usually comes from shares in companies that trade at low multiples and have stable cash flows. The trouble is, they don’t usually grow so well.

Both Judges Scientific and QXO come with risks. But I don’t think either business has become worse in the last month – and the share prices are much lower.

The post April opportunities: 2 heavily-discounted stocks to consider buying appeared first on The Twelfth Magpie.

A stock market rotation away from software and into materials has already pulled the FTSE 100 to parity with the S&P 500 over the last five years. And there might be more to come.

The Little Red Hen

In the story of The Little Red Hen, none of the title character’s friends wants to help with the work involved in making bread. But they’re interested in eating it.

The story doesn’t end well for them – those who don’t participate when there’s work to be done don’t get to join in with eating the bread. And there’s a lesson here for investors.

Amazon and Microsoft were very popular with investors when their earnings were growing rapidly. But huge artificial intelligence (AI) spending means it’s a different story now.

By contrast, the likes of Antofagasta and Anglo American are in fashion as the materials needed to build data centres are in high demand. That however, is a recent development.

There’s a good case for thinking that Amazon and Microsoft are planting the seeds for some huge cash generation in future. But there’s always a risk those seeds won’t grow.

Equally, it might well not be too late to consider buying Antofagasta and Anglo American. But investors who have been patient with these stocks are now demanding high prices.

Growth prospects

So where can investors look to find opportunities in today’s market? One of the names I’m looking to buy for my portfolio in March is Judges Scientific (LSE:JDG). 

Demand for scientific instruments has fallen away since the end of the pandemic. And the US government’s move to cut back on research funding has taken things down further.

On top of this, the firm has had a recent change of CEO, which might be disruptive to the strategy that has served it so well to date. That’s an important risk to consider.

As a result, investors don’t want to know and the stock now trades at much lower valuation multiples. But there are some very strong signs that a recovery might be on the cards in 2026.

The US Congress has rejected the proposed cuts to the National Institutes of Health. Instead, a $415m increase has been included, removing uncertainty and also boosting funding.

That’s extremely positive for the company’s overall outlook, but the little hen’s bread isn’t starting to show up yet. And that’s why I’m looking to buy it today and wait.

Stock market rotation

I think the established order of the stock market over the last few years is starting to shift. And if I’m right, that could be a very good thing for UK stocks that have been out of favour recently. 

Rather than the stocks that have been climbing recently, I’m looking for those that might be next to move. And the latest developments in the US mean Judges Scientific is on my list.

The post Why UK stocks could be set to outperform appeared first on The Twelfth Magpie.

While that’s changed a little bit in recent months, I’m still looking for opportunities to buy UK stocks. And there are a few companies that I’ve got my eye on for the month ahead.

The quality growth stock

Diploma‘s (LSE:DPLM) a FTSE 100 industrial components and equipment distributor. It’s not a stock I own, which is a pity because the company’s grown impressively in recent years. 

A strategy of buying smaller businesses and incorporating them into its network has generated outstanding growth. And it’s also well-protected from artificial intelligence (AI) disruption.

The risk with this approach is that there’s always a chance the firm might overpay for an acquisition. And although the company has an outstanding record – especially in recent years – success is never guaranteed.

The more the company grows though, the more its scale gives it advantages over the competition. The stock trades at a high price-to-earnings (P/E) multiple, but I think it’s worth considering.

The under-the-radar winner

Vistry‘s (LSE:VTY) a FTSE 250 housebuilder. The industry hasn’t been in a good way recently, but the latest £39bn affordable housing programme is set to launch. 

That means local authorities, housing associations, and other providers are going to be looking for builders to partner with on building projects. And this is what Vistry specialises in. 

Partnerships can be complicated and they definitely introduce new risks, but it’s a potential opportunity for a company that has a £2.3bn market value.

This seems to have largely gone unnoticed by investors. I already own Vistry shares in my portfolio, but I’m not averse to adding to my position at the current valuation.

The wildcard

Judges Scientific‘s (LSE:JDG) a scientific instrument company. And the stock has fallen 39% in the last 12 months as weak demand – especially from the US – has been weighing on sales. 

There are strong reasons though, for thinking that this might be set to pick up. The US Congress has rejected the administration’s proposed cuts to research budgets, opting to increase them instead.

To some extent, this highlights the key risk of selling primarily into markets where supply depends on government spending. That’s something that the company doesn’t control and can’t really influence.

Nonetheless, I think the stock is in a really interesting position. While management’s latest guidance was relatively conservative, there are reasons to expect business to pick up in 2026.

Which one to choose?

I like all three stocks, but my favourite is Judges Scientific. I can see strong long-term potential with the added boost of a potential recovery in 2026 for the markets it sells into.

I’m a big fan of Diploma, but I think I’ll get a better opportunity further into the future. And Vistry’s a very worthy candidate, but its long-term prospects just look slightly weaker to me.

That’s why I’m looking to buy Judges Scientific for my own portfolio. But I think all three are well worth considering for investors trying to find opportunities in the current market.

The post 3 UK stocks: which should I buy in March? appeared first on The Twelfth Magpie.

Nowadays in the UK, a Junior ISA could be one way for the next Warren Buffett to own shares at such a young age.

But I think investors of all ages can learn a lot from how the multibillionaire started out in the stock market under his own steam.

Buffett’s first move

Warren Buffett bought three shares in what is now CITGO for $38 apiece, so the total was $114.

In reality of course, the total cost was likely greater. Even today, one of the first lessons any investors learn is how stockbroking commissions and other charges can add up.

That was much worse back in the 1940s before online investing, but today it is still worth comparing share-dealing accounts and Stocks and Shares ISAs when hunting for a cost-effective way to invest.

Given the ravages of inflation, $114 back in 1942 is worth roughly $2,383 today. Not bad at all for an 11-year-old schoolboy who had saved up money from a paper round for the purchase.

In fact, I think that is also instructive. Buffett was marshalling his resources and generating cash under his own steam to invest.

Follow good investment principles from day one

At today’s exchange rate (with a far weaker pound than in 1942), $2,383 would be worth around £1,754.

That is plenty of money to avoid one mistake Warren Buffett made with his first investment – a lack of diversification.

Putting all your money into one share without spreading your risk is a schoolboy error. Warren Buffett was indeed a schoolboy when he did it – but the rest of us have no excuse.

Buying great businesses at attractive prices

Early in his career, Buffett was a value investor who was willing to buy into dying businesses as long as the share price looked cheap enough.

He later changed his focus to invest in what he saw as great companies at attractive prices.

Using some Buffett principles, one share I think investors should consider is Judges Scientific (LSE: JDG).

The company has grown through acquisition and owns a range of small and medium-sized instrument manufacturers serving specialist users like scientific labs. In that market, accuracy matters, so customers are willing to pay for quality.

But one challenge lately has been lacklustre demand in the US. I continue to see that and an uneven post-pandemic demand recovery in China as risks.

That helps explain why the share has lost 40% of its value over the past year. Now selling for 31 times earnings, this still looks more expensive than I am normally comfortable paying as an investor.

But I think Judges’ unique assets, pricing power and cash generative business model could help earnings grow handily in coming years.

From a long-term perspective, like the one Warren Buffett takes, I see it as a share to consider.

The post Want to invest with the same amount Warren Buffett spent on his first ever share buy? Here’s how! appeared first on The Twelfth Magpie.

Despite strong gains from the FTSE 100 recently, I think some quality stocks have been discarded by the stock market. And that’s where I’m looking for potential buying opportunities. 

Compass Group

In general, I like businesses able to charge customers lower prices than their competitors while still making more money. That’s why Compass Group (LSE:CPG) stands out to me.

The contract catering firm’s size allows it to negotiate better prices from suppliers by ordering in bulk. And it uses this advantage to charge customers less and fend off competition. 

The stock’s down 14% since the start of the year as investors weigh a few risks. One is the threat of anti-obesity medication and another is US hospitals finding themselves under financial pressure.

Importantly though, the company’s competitive advantage is still firmly intact. Nobody’s likely to match its scale any time soon and that’s why I think it’s worth considering at today’s prices.

Rentokil

Rentokil (LSE:RTO) shares fell 7% on Thursday (12 February). The reason is that one of the main risks – the amount of debt on its balance sheet – has become more of an issue.

The firm has a lot of debt after a huge acquisition a couple of years ago. And while it’s actually bringing its debt level down, it’s doing this with cash already borrowed at a higher rate. 

Investors should watch the debt maturities, but I think the business is likely to be one of the most durable around. Pest control isn’t going to be disrupted by AI or anti-obesity drugs.

Rentokil’s big acquisition brought a lot of debt, but it also made it the market leader. That’s a very valuable long-term position to be in, which is why it’s a stock I’m watching closely at the moment.

Judges Scientific

By comparison, Judges Scientific (LSE:JDG) is a tiny operation. But the scientific instrument company is my number-one UK stock for investors to consider at the moment. 

The share price is down 32% in the last 12 months. That’s largely because of weak demand from the US, where funding for scientific research has been under a lot of pressure from the government.

This is entirely out of Judges Scientific’s hands and thus represents a risk. Congress however, recently rejected the administration’s proposals (and increased budgets instead of cutting them). 

That should be a huge boost for the business. And while it isn’t showing up in the share price yet, I think this could be a great time to buy shares in a company with some terrific long-term prospects. 

Beyond Rolls-Royce

Rolls-Royce has been a brilliant stock for investors over the last few years. And the reason’s simple — it’s a quality business, but its shares were trading at a discounted price.

The question for investors is where to find that combination in today’s stock market. And Compass Group, Rentokil, and Judgest Scientific all fit into that category.

I think investors would be wise to give any of them a closer look. While I’m favouring Judges Scientific right now, I see all three as worthy candidates for consideration

The post 3 UK stocks I like more than Rolls-Royce right now appeared first on The Twelfth Magpie.